Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $172.7 million.

  • Oncology Institute's Liabilities and Shareholders Equity fell 868.61% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.1 million, marking a year-over-year decrease of 1455.18%. This contributed to the annual value of $172.7 million for FY2024, which is 1745.51% down from last year.
  • According to the latest figures from FY2024, Oncology Institute's Liabilities and Shareholders Equity is $172.7 million, which was down 1745.51% from $209.2 million recorded in FY2023.
  • Oncology Institute's Liabilities and Shareholders Equity's 5-year high stood at $261.7 million during FY2022, with a 5-year trough of $65.7 million in FY2020.
  • In the last 5 years, Oncology Institute's Liabilities and Shareholders Equity had a median value of $203.4 million in 2021 and averaged $182.5 million.
  • Per our database at Business Quant, Oncology Institute's Liabilities and Shareholders Equity skyrocketed by 20970.03% in 2021 and then tumbled by 2003.52% in 2023.
  • Oncology Institute's Liabilities and Shareholders Equity (Annual) stood at $65.7 million in 2020, then surged by 209.7% to $203.4 million in 2021, then rose by 28.62% to $261.7 million in 2022, then fell by 20.04% to $209.2 million in 2023, then fell by 17.46% to $172.7 million in 2024.
  • Its last three reported values are $172.7 million in FY2024, $209.2 million for FY2023, and $261.7 million during FY2022.